rivastigmine has been researched along with 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 4 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amooru, GD; Ampasala, DR; Darla, MM; Devineni, SR; Eadlapalli, S; Kotapati, KV; Palaka, BK; Penumala, M; Shaik, JB; Vadde, R | 1 |
| Chen, Q; Digiacomo, M; Nesi, G; Pi, R; Rapposelli, S; Sestito, S; Wang, S; Yang, X | 1 |
| Brazzolotto, X; Colletier, JP; Coquelle, N; Gobec, S; Jukič, M; Knez, D; Kos, J; Mravljak, J; Nachon, F; Pišlar, A; Sova, M; Žakelj, S | 1 |
| Chen, C; Fu, J; Hu, M; Li, X; Shao, S; Shi, G; Wang, D; Wu, S; Zhang, D; Zhang, T; Zhou, Y | 1 |
| Bertini, S; Chen, Q; Chiellini, G; He, X; Lu, J; Pi, R; Pomelli, C; Rapposelli, S; Sestito, S; Wang, S | 1 |
| Feng, F; He, S; Jiang, H; Jiang, X; Liu, W; Qu, W; Sun, H; Zhou, J | 1 |
| Cheng, X; Liu, W; Ma, Q; Sang, Z; Shi, J; Tan, Z; Wang, K; Wei, R; Yu, L; Zhao, Y; Zhu, G | 1 |
| Benek, O; Benkova, M; Dolezal, R; Hepnarova, V; Hrabinova, M; Janockova, J; Jun, D; Kobrlova, T; Korabecny, J; Kucera, T; Mezeiova, E; Prchal, L; Sobolova, K; Soukup, O | 1 |
| Cao, Z; Cong, S; Deng, Y; Liu, Z; Song, Q; Tan, Z; Yu, G | 1 |
| Chowdhury, SR; Fu, L; Gu, J; Hu, Y; Jiang, F; Lam, C; Lei, S; Lu, D; Tavallaie, MS; Wang, J | 1 |
1 review(s) available for rivastigmine and 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid
| Article | Year |
|---|---|
Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms.
Topics: Animals; Drug Combinations; Drug Delivery Systems; Drug Design; Humans; Ligands | 2019 |
9 other study(ies) available for rivastigmine and 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid
| Article | Year |
|---|---|
Synthesis, pharmacological assessment, molecular modeling and in silico studies of fused tricyclic coumarin derivatives as a new family of multifunctional anti-Alzheimer agents.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Binding Sites; Butyrylcholinesterase; Chemistry Techniques, Synthetic; Cholinesterase Inhibitors; Computer Simulation; Coumarins; Drug Evaluation, Preclinical; Galantamine; Humans; Hydrogen Peroxide; Male; Mice, Inbred BALB C; Models, Molecular; Neuroprotective Agents; Neurotoxicity Syndromes | 2016 |
Nature-based molecules combined with rivastigmine: A symbiotic approach for the synthesis of new agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Biological Products; Butyrylcholinesterase; Cell Death; Cell Line, Tumor; Cell Survival; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Free Radical Scavengers; Glutamic Acid; Humans; Molecular Structure; Neuroprotective Agents; Peptide Fragments; Protein Aggregates; Rivastigmine; Structure-Activity Relationship | 2017 |
Multi-target-directed ligands for treating Alzheimer's disease: Butyrylcholinesterase inhibitors displaying antioxidant and neuroprotective activities.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Butyrylcholinesterase; Caco-2 Cells; Cell Line, Tumor; Cholinesterase Inhibitors; Drug Design; Humans; Ligands; Models, Molecular; Neuroprotective Agents; Piperidines | 2018 |
Design, synthesis, and evaluation of isoflavone analogs as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Butyrylcholinesterase; Cell Line; Cell Survival; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Humans; Inflammation; Isoflavones; Lipopolysaccharides; Male; Mice; Mice, Inbred ICR; Models, Molecular; Molecular Structure; Neuroprotective Agents; Receptors, Histamine H3; Structure-Activity Relationship | 2019 |
Multi-targeted ChEI-copper chelating molecules as neuroprotective agents.
Topics: Acetylcholinesterase; Animals; Butyrylcholinesterase; Cell Line, Transformed; Chelating Agents; Cholinesterase Inhibitors; Coordination Complexes; Copper; Free Radical Scavengers; Mice; Neuroprotective Agents; Rivastigmine | 2019 |
Apigenin-rivastigmine hybrids as multi-target-directed liagnds for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Apigenin; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Ligands; Microsomes, Liver; Molecular Docking Simulation; Molecular Structure; Neuroprotective Agents; Rats; Rivastigmine; Structure-Activity Relationship; Zebrafish | 2020 |
Discovery of novel berberine derivatives with balanced cholinesterase and prolyl oligopeptidase inhibition profile.
Topics: Berberine; Blood-Brain Barrier; Cell Line, Tumor; Cholinesterase Inhibitors; Cholinesterases; Drug Design; Humans; Prolyl Oligopeptidases | 2020 |
Novel 3-benzylidene/benzylphthalide Mannich base derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Benzofurans; Benzylidene Compounds; Blood-Brain Barrier; Butyrylcholinesterase; Cholinesterase Inhibitors; Copper; Dose-Response Relationship, Drug; Electrophorus; Female; Humans; Male; Mannich Bases; Mice; Mice, Inbred Strains; Models, Molecular; Molecular Structure; Neuroprotective Agents; PC12 Cells; Peptide Fragments; Protein Aggregates; Rats; Structure-Activity Relationship | 2021 |
Synthesis, biological evaluation and molecular modeling of benzofuran piperidine derivatives as Aβ antiaggregant.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Benzofurans; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Models, Molecular; Molecular Structure; Neuroprotective Agents; Piperidines; Protein Aggregates; Protein Aggregation, Pathological; Structure-Activity Relationship | 2021 |